智通财经APP获悉，百时美施贵宝(BMY.US)第四季度营收为123亿美元，超过市场预期，其中Eliquis和Revlimid的销售超过预期。最近上市的两种药物——心脏病药物Camzyos和自身免疫治...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

百时美施贵宝(BMY.US)第四季度营收为123亿美元，超过市场预期，其中Eliquis和Revlimid的销售超过预期。最近上市的两种药物——心脏病药物Camzyos和自身 ...

Shares of NATCO Pharma plunged 19 per cent on Thursday, February 13, following the company’s disappointing Q3 FY25 results, ...

Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales last year.

Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs.

Bristol Myers Squibb & Co (NYSE:BMY) posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 ...

Indian pharmaceutical (IT) major, Dr Reddy's Laboratories, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Thursday, January 23, 2025 ...

Sun Pharma's Q3 earnings may see a slight setback in margins, pressured by increased R&D expenses and a lower contribution from cancer drug Revlimid.

Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot ...

The brokerage is optimistic about the pharmaceutical company's proactive strategies to lessen the effects of the patent expiration for its blockbuster drug Revlimid in 2026. The brokerage noted ...